Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
OCRX > SEC Filings for OCRX > Form 8-K on 13-Jun-2014All Recent SEC Filings

Show all filings for OCERA THERAPEUTICS, INC.

Form 8-K for OCERA THERAPEUTICS, INC.


13-Jun-2014

Change in Directors or Principal Officers, Submission of Matters to a Vo


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 11, 2014, the Board of Directors (the "Board") of Ocera Therapeutics, Inc. (the "Company") appointed Sharon Tetlow as Acting Chief Financial Officer and Treasurer of the Company. The Board also selected Ms. Tetlow to perform the duties of the Company's principal financial officer and principal accounting officer. On June 2, 2014, the Company entered into a Consulting Agreement (the "Consulting Agreement") with Danforth Advisors, LLC ("Danforth"), pursuant to which Ms. Tetlow will provide the Company with certain strategic and financial advice and support services during the one-year period beginning on June 2, 2014. The Company will pay Danforth a consulting fee of $325 per hour for Ms. Tetlow's services. The Consulting Agreement may be terminated either by the Company or by Danforth without cause upon 90 days' prior written notice.

Ms. Tetlow, age 54, has worked as a Managing Director at Danforth, which provides financial and operational support for emerging life science and renewable energy companies, since April 2013. Prior to working at Danforth, Ms. Tetlow served as the Chief Financial Officer of Pathwork Diagnostics, a commercial stage molecular diagnostics company, from 2011 until March 2013. Ms. Tetlow served as the Senior Vice President, Chief Financial Officer of Cell Genesys from July 2005 to October 2009, as a Venture Partner of Apax Partners from October 2004 to February 2005, and as Chief Financial Officer of diaDexus from February 1999 to October 2004. Ms. Tetlow holds an B.S. from the University of Delaware and an M.B.A. from Stanford University.

There are no related party transactions between the Company and Ms. Tetlow, and Ms. Tetlow is neither related to, nor does she have any relationship with, any existing member of the Board or any executive officer of the Company.



Item 5.07 Submission of Matters to a Vote of Security Holders.

The Company's 2014 Annual Meeting of Stockholders (the "Annual Meeting") was held on June 11, 2014. A total of 13,301,960 shares of the Company's common stock were present or represented by proxy at the Annual Meeting. At the Annual Meeting, the stockholders voted on the following three proposals and cast their votes as described below.

Proposal 1. The individuals listed below were elected at the Annual Meeting to serve until the annual meeting of stockholders in 2015 and until their respective successors are duly elected and qualified or until their earlier resignation or removal.

                                                      BROKER NON-
                                 FOR       WITHHELD      VOTES
Eckard Weber, M.D.            11,330,053    45,783     1,926,124
Jean-Paul Castaigne, M.D.     11,330,053    45,783     1,926,124
Lars G. Eckman, M.D., Ph.D.   11,296,541    79,295     1,926,124
Linda S. Grais, M.D.          11,360,076    15,760     1,926,124
Nina Kjellson                 11,360,176    15,660     1,926,124
Michael Powell, Ph.D.         11,360,176    15,660     1,926,124
Franck S. Rousseau, M.D.      11,359,853    15,983     1,926,124
Anne VanLent                  11,360,076    15,760     1,926,124
Wendell Wierenga, Ph.D.       11,330,053    45,783     1,926,124


Proposal 2. The Company's stockholders approved the non-binding, advisory resolution on the executive compensation of the Company's named executive officers.

                                 BROKER NON-
   FOR       AGAINST   ABSTAIN      VOTES
10,475,787   256,385   643,664    1,926,124

Proposal 3. The Company's stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2014.

FOR AGAINST ABSTAIN
13,300,558 1,402 0


  Add OCRX to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for OCRX - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.